| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Carnosic acid has multiple targets. It is a lipid absorption inhibitor and activates the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. It also inhibits β-catenin-dependent transcription and destabilizes oncogenic β-catenin in colon cancer cells.
|
|---|---|
| ln Vitro |
Dried leaves of sage and rosemary have especially high amounts of carnosic acid, a neurogenic diterpene found deep inside the leaves of Lamiaceae plants. It has been demonstrated that carnosic acid inhibits oxidation and modulates inhibition. Based mostly on in vitro investigations, carbosic acid has been widely claimed to offer therapeutic promise in several cancer types. In the current experimental models of dementia, carnosic acid still has neuroprotective effects, mainly via activation of the antioxidant NRF2/ARE [1].
In vitro, Carnosic acid inhibits lipid peroxidation induced by NADH or NADPH oxidation. It scavenges peroxyl radicals and H2O2, reduces cytochrome C, and inhibits superoxide anion production. It also inhibits cell proliferation and induces apoptosis in various tumor cell lines. |
| ln Vivo |
In vivo, Carnosic acid has been shown to protect neurons through activation of the Keap1/Nrf2 pathway. It inhibits cell growth and has anti-inflammatory and antibacterial effects. It is also an angiogenesis modulating agent.
|
| Enzyme Assay |
In vitro assays for Carnosic acid measure its antioxidant capacity. This includes its ability to scavenge free radicals (e.g., DPPH assay), inhibit lipid peroxidation, and reduce cytochrome C. Its activation of the Nrf2 pathway can be measured by assessing the expression of Nrf2 target genes.
|
| Cell Assay |
In vitro cell-based assays are performed in various cancer cell lines, such as colon cancer and medulloblastoma (MB) cells. The effects on cell proliferation, viability, and apoptosis are measured. The impact on signaling pathways, such as β-catenin, is also assessed via Western blotting.
|
| Animal Protocol |
In vivo activity is evaluated in animal models of disease. For example, its neuroprotective effects are studied in models of neurodegeneration. Its anticancer activity can be assessed in xenograft models, where tumor growth and angiogenesis are monitored.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Carnosic acid are not extensively detailed. As a natural product with oral activity, it is expected to be absorbed and distributed. However, its bioavailability may be limited due to poor solubility or rapid metabolism.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for Carnosic acid is not available in standard research literature. As a widely consumed dietary component from rosemary, it is generally recognized as safe (GRAS) at normal dietary levels. High doses may have pharmacological effects and potential toxicity.
|
| References | |
| Additional Infomation |
Carnosic acid is an abietic diterpenoid compound with the structure abietic-8,11,13-triene, substituted with hydroxyl groups at positions 11 and 12 and a carboxyl group at position 20. It was isolated from rosemary (Rosmarinus officinalis) and sage (Salvia officinalis) and possesses anti-angiogenic, antitumor, antioxidant, and anti-HIV activities. It can be used as an antitumor agent, antioxidant, HIV protease inhibitor, angiogenesis regulator, apoptosis inducer, plant metabolite, anti-inflammatory agent, and food preservative. It is an abietic diterpenoid compound, a C3-cyclic compound, a catechol compound, and a monocarboxylic acid. It is the conjugate acid of Carnosic acid. Carnosic acid has been found in sage (Salvia officinalis), cumin (Cuminum cyminum), and other organisms with relevant data. See also: Rosemary (partial).
Carnosic acid is a major bioactive component of rosemary and is used as a natural food preservative due to its antioxidant properties. Its ability to activate the Nrf2 pathway makes it a promising lead compound for developing therapies for neurodegenerative diseases, cancer, and inflammatory conditions. |
| Molecular Formula |
C20H28O4
|
|---|---|
| Molecular Weight |
332.43
|
| Exact Mass |
332.198
|
| Elemental Analysis |
C, 72.26; H, 8.49; O, 19.25
|
| CAS # |
3650-09-7
|
| PubChem CID |
65126
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
506.4±50.0 °C at 760 mmHg
|
| Melting Point |
190 °C
|
| Flash Point |
274.2±26.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.576
|
| LogP |
4.93
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
500
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O([H])C([C@@]12C3=C(C(=C(C([H])(C([H])([H])[H])C([H])([H])[H])C([H])=C3C([H])([H])C([H])([H])[C@@]1([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])C2([H])[H])O[H])O[H])=O
|
| InChi Key |
QRYRORQUOLYVBU-VBKZILBWSA-N
|
| InChi Code |
InChI=1S/C20H28O4/c1-11(2)13-10-12-6-7-14-19(3,4)8-5-9-20(14,18(23)24)15(12)17(22)16(13)21/h10-11,14,21-22H,5-9H2,1-4H3,(H,23,24)/t14-,20+/m0/s1
|
| Chemical Name |
(4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylic acid
|
| Synonyms |
Carnosic Acid; Salvin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~130 mg/mL (~391.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (6.26 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0082 mL | 15.0408 mL | 30.0815 mL | |
| 5 mM | 0.6016 mL | 3.0082 mL | 6.0163 mL | |
| 10 mM | 0.3008 mL | 1.5041 mL | 3.0082 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
